The potential of induced pluripotent stem cells for discriminating neurodevelopmental disorders. (31st August 2020)

• Record Type: Journal Article
• Authors: Stock, Ricarda; Jeckel, Pauline; Kraushaar, Udo; Wüst, Richard; Fallgatter, Andreas; Volkmer, Hansjürgen
• Is Part Of: Stem cells translational medicine. Volume 10:Number 1(2021)
• Page Start: 50
• Page End: 56
• Publication Date: 2020-08-31
• Subjects: autism -- calcium imaging -- electrophysiology -- iPSC -- schizophrenia -- transcriptome; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.20-0206
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: Studying human disease-specific processes and mechanisms in vitro is limited by a lack of valid human test systems. Induced pluripotent stem cells (iPSCs) evolve as an important and promising tool to better understand the molecular pathology of neurodevelopmental disorders. Patient-derived iPSCs enable analysis of unique disease mechanisms and may also serve for preclinical drug development. Here, we review the current knowledge on iPSC models for schizophrenia and autism spectrum disorders with emphasis on the discrimination between them. It appears that transcriptomic analyses and functional read-outs are the most promising approaches to uncover specific disease mechanisms in vitro. Abstract : Somatic cells from thoroughly diagnosed patients suffering from neuropsychiatric disorders can be reprogrammed into disease-specific induced pluripotent stem cells to study neurodevelopmental pathologies. Differentiated cells can be used for drug development and high-throughput screening within a variety of robust and reproducible assays.